In vitro characterization of PlySK1249, a novel phage lysin, and assessment of its antibacterial activity in a mouse model of Streptococcus agalactiae bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6276-6283

  Oechslin, Frank ^a   Daraspe, Jean ^a   Giddey, Marlyse ^a   Moreillon, Philippe ^a   Resch, Grégory ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOPHAGE SK1249; FEMALE; GENE PRODUCT; GROUP B STREPTOCOCCAL INFECTION; HOST RANGE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS DYSGALACTIAE EQUISIMILIS; STREPTOCOCCUS PHAGE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; ESCHERICHIA COLI; FEMALE; GENOME, BACTERIAL; MICE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE;

EID: 84887476185     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01701-13     Document Type: Article

References (26)

1. Lancefield RC. 1933. A serological differentiation of human and other groups of hemolytic streptococci. J. Exp. Med. 57:571-595.
2. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, Craig AS, Schaffner W, Zansky SM, Gershman K, Stefonek KR, Albanese BA, Zell ER, Schuchat A, Schrag SJ. 2008. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 299:2056-2065.
3. Money DM, Dobson S. 2004. The prevention of early-onset neonatal group B streptococcal disease. J. Obstet. Gynaecol. Can. 26:826-840.
4. Muller AE, Oostvogel PM, Steegers EA, Dorr PJ. 2006. Morbidity related to maternal group B streptococcal infections. Acta Obstet. Gynecol. Scand. 85:1027-1037.
5. Jackson LA, Hilsdon R, Farley MM, Harrison LH, Reingold AL, Plikaytis BD, Wenger JD, Schuchat A. 1995. Risk factors for group B streptococcal disease in adults. Ann. Intern. Med. 123:415-420.
6. Yanai H, Hamasaki H, Tsuda N, Adachi H, Yoshikawa N, Moriyama S, Masui Y, Mishima S. 2012. Group B streptococcus infection and diabetes: a review. J. Microbiol. Antimicrob. 4:1-5.
7. Centers for Disease Control and Prevention. 2010. Prevention of perinatal group B streptococcal disease. Morb. Mortal. Wkly. Rep. 59:1-4.
8. Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamane K, Shibata N, Nagano N, Kato H, Shibayama K, Arakawa Y. 2008. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52:2890-2897.
9. Dahesh S, Hensler ME, Van Sorge NM, Gertz RE, Jr, Schrag S, Nizet V, Beall BW. 2008. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob. Agents Chemother. 52:2915-2918.
10. Sendi P, Zimmerli W. 2012. Comment on: Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J. Antimicrob. Chemother. 67:1050-1051.
11. Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, Juni BA, Cieslak PR, Farley MM, Dumas NB, Schrag SJ, Lynfield R. 2008. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect. Dis. Obstet. Gynecol. 2008:727505. doi:10.1155/2008/727505.
12. Bergseng H, Afset JE, Radtke A, Loeseth K, Lyng RV, Rygg M, Bergh K. 2009. Molecular and phenotypic characterization of invasive group B streptococcus strains from infants in Norway 2006-2007. Clin. Microbiol. Infect. 15:1182-1185.
13. Fischetti VA. 2008. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol. 11:393-400.
14. Schmitz JE, Schuch R, Fischetti VA. 2010. Identifying active phage lysins through functional viral metagenomics. Appl. Environ. Microbiol. 76: 7181-7187.
15. Loeffler JM, Djurkovic S, Fischetti VA. 2003. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect. Immun. 71: 6199-6204.
16. Dell RB, Holleran S, Ramakrishnan R. 2002. Sample size determination. ILAR J. 43:207-213.
17. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. 2011. PHAST: a fast phage search tool. Nucleic Acids Res. 39:W347-W352.
18. Frankel MB, Hendrickx AP, Missiakas DM, Schneewind O. 2011. LytN, a murein hydrolase in the cross-wall compartment of Staphylococcus aureus, is involved in proper bacterial growth and envelope assembly. J. Biol. Chem. 286:32593-32605.
19. Pritchard DG, Dong S, Baker JR, Engler JA. 2004. The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. Microbiology 150:2079-2087.
20. Baker JR, Liu C, Dong S, Pritchard DG. 2006. Endopeptidase and glycosidase activities of the bacteriophage B30 lysin. Appl. Environ. Microbiol. 72:6825-6828.
21. Cheng Q, Nelson D, Zhu S, Fischetti VA. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49:111-117.
22. Pritchard DG, Dong S, Kirk MC, Cartee RT, Baker JR. 2007. LambdaSa1 and LambdaSa2 prophage lysins of Streptococcus agalactiae. Appl. Environ. Microbiol. 73:7150-7154.
23. Arnau J, Lauritzen C, Petersen GE, Pedersen J. 2006. Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins. Protein Expr. Purif 48:1-13.
24. Holtje JV, Tomasz A. 1976. Purification of the pneumococcal Nacetylmuramyl-L-alanine amidase to biochemical homogeneity. J. Biol. Chem. 251:4199-4207.
25. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. 2005. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob. Agents Chemother. 49: 4789-4792.
26. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. 2013. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57:2743-2750.